Skip to main content

Table 1 Results of univariate and multivariate models assessing HR of exposures on lymphoma development in SLE patients

From: Lymphoma risk in systemic lupus: effects of treatment versus disease activity

Variable Univariate HR (95% CI) Partially adjusted model (95% CI) Multivarate HR (95% CI)
Cyclophosphamide (CY) ever 1.73 (0.90 to 3.33) 1.99 (1.00 to 3.96) 1.95 (0.61 to 6.22)
Cumulative CY >6 g 1.51 (0.63 to 3.62) - 0.79 (0.18 to 3.54)
Azathioprine (AZA) ever 0.82 (0.45 to 1.52) - 1.28 (0.53 to 3.07)
Cumulative AZA >36.5 g 0.49 (0.19 to 1.25) - 0.46 (0.14 to 1.54)
Methotrexate ever used 0.99 (0.45 to 2.16) - 0.79 (0.30 to 2.05)
Mycophenolate ever used 1.38 (0.58 to 3.29) - 1.74 (0.70 to 4.34)
Antimalarials ever used 1.47 (0.80 to 2.69) - 1.39 (0.69 to 2.78)
Glucocorticosteroids (GC) ever 1.39 (0.75 to 2.56) - 1.03 (0.40 to 2.64)
Cumulative GCa >3.5 g 1.27 (0.75 to 2.17) - 1.59 (0.69 to 3.67)
Disease activity (second tertile)b 1.00 (0.55 to 1.82) - 1.10(0.56 to 2.14)
Disease activity (third tertile) 0.43 (0.22 to 0.84) 0.49 (0.27 to 0.90) 0.52 (0.24 to 1.12)
Outside North America 1.04 (0.53 to 2.05) - 1.06 (0.45 to 2.50)
Male 2.47 (1.24 to 4.92) - 2.21 (1.05 to 4.66)
Age 1.05 (1.03 to 1.07) 1.04 (1.03 to 1.06) 1.05 (1.03 to 1.07)
White race/ethnicity 0.97 (0.55 to 1.71) - 0.86 (0.46 to 1.59)
Calendar year 1.01 (0.98 to 1.05) - 0.98 (0.94 to 1.02)
Sjögren's syndrome 1.29 (0.66 to 2.54) - 1.21 (0.53 to 2.78)
  1. aSystemic glucocorticosteroids, considered in prednisone equivalent doses. bMean adjusted SLE Disease Activity-2K (SLEDAI-2K).